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Abstract 
Cytochrome (CYP) P450 enzymes have a primary role in antidepressant metabolism and variants in 
these polymorphic genes are targets for pharmacogenetic investigation.  This is the first meta-analysis 
to investigate how CYP2C19 polymorphisms predict citalopram/escitalopram efficacy and side 
effects.  
CYP2C19 metabolic phenotypes comprise poor metabolizers (PM), intermediate and intermediate+ 
metabolizers (IM; IM+), extensive and extensive+ metabolizers (EM [wild type]; EM+) and ultra-
rapid metabolizers (UM) defined by the two most common CYP2C19 functional polymorphisms 
(rs4244285 and rs12248560) in Caucasians. These polymorphisms were genotyped or imputed from 
genome-wide data in four samples treated with citalopram or escitalopram (GENDEP, STAR*D, 
GenPod, PGRN-AMPS). Treatment efficacy was assessed by standardized percentage symptom 
improvement and by remission. Side effect data were available at weeks 2-4, 6 and 9 in three samples. 
A fixed-effects meta-analysis was performed using EM as the reference group. 
Analysis of 2558 patients for efficacy and 2037 patients for side effects showed that PMs had higher 
symptom improvement (SMD=0.43, CI=0.19-0.66) and higher remission rates (OR=1.55, CI=1.23-
1.96) compared to EMs. At weeks 2-4, PMs showed higher risk of gastro-intestinal (OR=1.26, 
CI=1.08-1.47), neurological (OR=1.28, CI=1.07-1.53) and sexual side effects (OR=1.52, CI=1.23-
1.87; week 6 values were similar). No difference was seen at week 9 or in total side effect burden. 
PMs did not have higher risk of dropout at week 4 compared to EMs. Antidepressant dose was not 
different among CYP2C19 groups. 
CYP2C19 polymorphisms may provide helpful information for guiding citalopram/escitalopram 
treatment, despite PMs being relatively rare among Caucasians (~2%).  
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1. Introduction 
Major depressive disorder (MDD) is a leading cause of disability-adjusted life years worldwide (GBD 
2015 Disease and Injury Incidence and Prevalence Collaborators, 2016). Although anti-depressant 
drugs can be an effective therapy, remission rates are disappointing, largely as a consequence of high 
variability in efficacy among individuals combined with early discontinuation or poor compliance 
due to side effects (Hodgson et al., 2012; Crawford et al., 2014). Genetic variants are considered key 
modulators of antidepressant efficacy and side effects (Cacabelos et al., 2012). Common variants 
were estimated to explain approximately 42% of inter-individual variability in antidepressant 
response (Tansey et al., 2013), confirming the role of genetic polymorphisms as promising markers 
to provide personalized treatments.  
Previous pharmacogenetic studies for antidepressant efficacy and side effects have focused on genes 
involved in antidepressant mechanisms of action (pharmacodynamics) or in antidepressant 
transport/metabolism (pharmacokinetics), including the cytochrome P450 genes (CYP450) (Fabbri 
and Serretti, 2015). These CYP450 genes are included in commercial pharmacogenetic tests (e.g. 
GeneSight Psychotropic, Genecept Assay™, YouScript Psychotropic (GTR: Genetic Testing 
Registry, 2017)). They form promising targets for personalizing antidepressant treatment, since they 
are responsible for antidepressant drug metabolism and their polymorphisms define phenotypic 
groups with different level of metabolic activity (Porcelli et al., 2011). An association between 
CYP450 metabolizer status (CYP450 metabolic phenotypes) and metabolite plasma levels has been 
consistently reported for antidepressants, but the association of CYP450 metabolic phenotypes with 
antidepressant efficacy and side effects is more controversial (Porcelli et al., 2011).  
 CYP2C19 is the primary CYP450 isoform responsible for the metabolism of citalopram and 
escitalopram, two commonly prescribed SSRIs (selective serotonin reuptake inhibitors) (Hicks et al., 
2015). Elevated drug concentrations have been observed in CYP2C19 poor metabolizers (PMs), 
which may increase the risk of adverse drug reactions, while CYP2C19 ultrarapid metabolizers (UMs) 
may have lower exposure to these drugs leading to treatment failure. CYP2C19-adjusted doses for 
citalopram and escitalopram have been estimated, but these were based on observed differences in 
drug pharmacokinetics, not differences in clinical outcomes of efficacy and side effects (Hicks et al., 
2015).  
Inconsistent associations between CYP2C19 metabolic phenotypes and citalopram/escitalopram 
outcomes have been observed, and several factors may have led to the contradictory results (Peters 
et al., 2008; Mrazek et al., 2011; Hodgson et al., 2014; Hodgson et al., 2015):  
1) Only a weak correlation exists between SSRI dose and efficacy. Drug plasma levels may not be 
associated with either efficacy or side effects, at least not linearly, and power to detect this association 
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is limited by several factors (e.g. difference between plasma and brain drug concentration) 
(Jakubovski et al., 2016; Hodgson et al., 2014; Hodgson et al., 2015; Florio et al., 2017);  
2) Pharmacodynamic mechanisms may modulate the association between CYP2C19 metabolic 
phenotypes and citalopram/escitalopram efficacy and some side effects, confounding the association 
between pharmacokinetic parameters and treatment outcomes (Jukić et al., 2016);  
3) CYP2C19 PM are rare, and studies may have lacked power to detect a pharmacogenetic association 
with this metabolic phenotype.  
In this study, we present the first meta-analysis to investigate association between CYP2C19 
metabolic phenotypes and citalopram/escitalopram efficacy and side effects. This large study aimed 
to identify a link between CYP2C19 metabolic phenotypes and treatment outcomes and to determine 
whether dose adjustments based on CYP2C19 metabolic phenotypes should be part of personalized 
medicine for antidepressant treatment.  
 
2. Experimental procedures 
2.1. Samples  
Four samples were included in this meta-analysis; all patients had a diagnosis of MDD and they were 
treated with citalopram or escitalopram for 8 weeks (PGRN-AMPS) or 12 weeks (GENDEP, 
STAR*D, GenPod). Clinical-demographic characteristics are reported in Supplementary Table 1, and 
show similarity across samples in mean age (~40 years old), percent of females (60-67%) and baseline 
severity (~22 ± 5 HAMD-17 equivalents).  
2.1.1. GENDEP 
The Genome-Based Therapeutic Drugs for Depression (GENDEP) project was a 12-week partially 
randomized open-label pharmacogenetic study with two active treatment arms. 867 patients with 
unipolar depression (ICD-10 or DSM-IV criteria) aged 19–72 years were recruited at nine European 
centres. Eligible participants were allocated to flexible-dosage treatment with either escitalopram 
(10–30 mg daily) or nortriptyline. Only 499 patients treated with escitalopram were included in the 
current meta-analysis. Severity of depression was assessed weekly by the Montgomery-Asberg 
Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979), Hamilton Rating Scale for 
Depression (HRSD–17) (Hamilton, 1967) and other measures. Side effects were assessed at baseline 
and then weekly using the Antidepressant Side-Effect Checklist (ASEC) and UKU Side Effect Rating 
Scale, with good agreement between them. The ASEC data were analysed for this study, since they 
have lower rates of missing data (Uher et al., 2009). Detailed information about the GENDEP study 
has been previously reported (Uher et al., 2010).  
2.1.2 STAR*D 
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The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was a NIMH-funded 
study to determine the effectiveness of different treatments for patients with MDD who have not 
responded to the first antidepressant treatment. A total of 4,041 non-psychotic MDD (DSM-IV 
criteria) patients aged between 18 and 75 years were enrolled from primary care or psychiatric 
outpatient clinics from 41 clinical sites around the US. Of these, 2,876 patients met the inclusion 
criterion of having at least moderate depression severity, among which 1,948 were genotyped using 
genome-wide arrays (Garriock et al., 2010). Severity of depression was assessed using the 16-item 
Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16) (Trivedi et al., 2004) 
at baseline, weeks 2, 4, 6, 9, and 12. Side effects were measured at the same time points using the 
Patient-Rated Inventory of Side Effects (PRISE). This study uses data from level 1, where all patients 
received citalopram (20-40 mg/day). Detailed description of the study design and population are 
reported elsewhere (Rush et al., 2004).  
2.1.3. PGRN-AMPS 
The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study 
(PGRN-AMPS) recruited 529 participants aged between 18 and 84 years with non-psychotic MDD 
recruited at inpatient and outpatient practices of the Department of Psychiatry and Psychology, Mayo 
Clinic, Rochester, Minnesota. Included participants were treated with either citalopram (n=167, dose 
20-40 mg/day) or escitalopram (n=353, dose 10-20 mg/day) and depressive symptoms were rated 
using QIDS-C16 as in STAR*D. Side effects were assessed using the PRISE scale at weeks 4 and 8. 
Further details were reported elsewhere (Ji et al., 2013). 
2.1.4. GenPod 
The GENetic and clinical Predictors Of treatment response in Depression (GenPod) was a multi-
centre randomized clinical trial of 601 patients aged between 18-74 years recruited in primary care 
who had an ICD-10 diagnosis of major depression of at least moderate severity as assessed by the 
Clinical Interview Schedule-Revised (CIS-R) (Lewis et al., 1992) and the Beck Depression Inventory 
(BDI) (Beck et al., 1961). No measure of side effects was available. Patients were recruited in three 
UK centres (Bristol, Birmingham and Newcastle). Individuals were randomly allocated to either 
reboxetine (4 mg twice daily) or citalopram (20 mg/day) treatment for 12 weeks and symptom 
severity was assessed using the BDI. 240 patients of European ancestry and treated with citalopram 
were included in this meta-analysis.  Further details about this study can be found elsewhere (Thomas 
et al., 2008). 
2.2. Outcomes 
2.2.1. Treatment efficacy 
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Treatment efficacy was measured by percentage symptom improvement and by remission at study 
endpoint (week 12 for GENDEP, STAR*D and GenPod; week 8 for PGRN-AMPS). Continuous 
measures, such as percentage improvement, capture more information and have higher power than 
cutoff-based dichotomous measures, however remission has a particular clinical relevance since it is 
associated with MDD prognosis (Streiner, 2002; Gaynes et al., 2009).  
The percentage symptom improvement was corrected for possible confounding variables (age, 
baseline severity, and center for multi-center studies) and then standardized in each sample to allow 
comparability across the different scales used to evaluate depressive symptoms.  
Remission was defined as a binary variable according to standard definitions (HRSD–17 ≤ 7 in 
GENDEP; QIDS-C16 ≤ 5 in STAR*D and PGRN-AMPS; BDI < 10 in GenPod). In GENDEP 
symptom improvement was calculated using the MADRS scale similarly to previous studies (Uher et 
al., 2010) while HRSD–17 was used to define remission given the stronger consensus about the 
threshold to identify remission on this scale in contrast to MADRS, where different definitions of 
remission have been reported (Li et al., 2016) (Jacobsen et al., 2015). 
HRSD–17 and QIDS-C16 missing values at follow-up were imputed using the best unbiased estimate 
from a mixed-effect linear regression model, with fixed linear and quadratic effects of time and 
random effects of individual and center of recruitment, following previously reported methods (Uher 
et al., 2010).  
2.2.2. Side effects 
Measures of side effects were available in GENDEP, STAR*D and PGRN-AMPS. In GENDEP we 
chose to use the ASEC because data was more complete than the UKU (Uher et al., 2009). In 
STAR*D and PGRN-AMPS side effects were assessed using the PRISE scale. Both scales use a 
rating of severity for each side effect (coded 0-3 in ASEC, and 0-2 in PRISE) which was dichotomized 
(0=absent, 1=present) for the meta-analysis. Side effects were grouped in categories that were 
assessed in these samples: gastro-intestinal (dry mouth, diarrhea, constipation, nausea or vomiting), 
cardiovascular (palpitations, dizziness or feeling light-headed on standing), central nervous system 
(headache, tremor, feeling like the room is spinning), sleep (insomnia, drowsiness or oversleeping) 
and sexual (loss of desire, trouble achieving orgasm, trouble with erection). These categories were 
analysed as dichotomous variables (presence of at least one side effect in each category). Study 
retention at week 4 was compared among CYP2C19 metabolic phenotypes since patients who did not 
benefit from treatment or had troubling side effects are expected to be lost from follow-up early in 
the study. To assess the overall severity of side effects, we summed the number of side effects 
reported, and dichotomized at the 3rd quartile of the distribution in each sample to study if CYP2C19 
groups were differently distributed among those patients having the most relevant burden of side 
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effects. We also calculated a standardized continuous measure of all side effects reflecting the whole 
distribution of side effect severity. Analyses on total side effect severity were performed only in 
GENDEP and STAR*D because raw data were not available in PGRN-AMPS.  
Antidepressant-induced side effects are more frequent at the beginning of treatment and then decrease 
(Uher et al., 2009). We therefore meta-analysed side effects at weeks 2-4 (no assessment was 
performed at week 2 in PGRN-AMPS), week 6 and weeks 8-9 (no assessment was performed at week 
8 in STAR*D while in GENDEP we used week 8 data because of lower missing rate compared to 
week 9).  
In GENDEP side effects were common at baseline in medication-free patients (Uher et al., 2009). 
We therefore performed a sensitivity analysis excluding side effects there were present also at 
baseline in drug-free GENDEP patients. 
2.3. Genotyping and definition of CYP2C19 metabolic phenotypes 
CYP2C19 metabolic phenotypes comprise poor metabolizers (PM), intermediate and intermediate+ 
metabolizers (IM; IM+), extensive and extensive+ metabolizers (EM [wild type]; EM+) and ultra-
rapid metabolizers (UM) defined by the two most common CYP2C19 functional polymorphisms 
(rs4244285 and rs12248560) which capture the CYP2C19 *1, *2 and *17 functional alleles 
(Supplementary Table 2) (Hodgson et al., 2014). These polymorphisms were directly genotyped in 
GENDEP using the AmpliChip CYP450 test (Hodgson et al., 2014) and they were imputed in the 
other samples using the Haplotype Reference Consortium (HRC version r1.1 2016) panel as reference 
and Minimac3. Pre-imputation quality control was performed according to standard criteria (variants 
with missing rate ≥ 5%; monomorphic variants; subjects with genotyping rate < 97%; subjects with 
gender discrepancies; subjects with abnormal heterozygosity; related subjects (identity by descent 
(IBD) >0.1875 (Anderson et al., 2010)); population outliers according to Eigensoft analysis of 
linkage-disequilibrium-pruned genetic data (Price et al., 2006); and non-white subjects). Imputation 
quality was assessed using R2 (Li et al., 2010) and comparing imputed and genotyped CYP2C19 
metabolic phenotypes in GENDEP. 
2.4. Statistical analysis 
Individual-level phenotypes and genotypes were available for all studies. A fixed-effects meta-
analysis was performed with the R package “Netmeta” (https://cran.r-
project.org/web/packages/netmeta/index.html). This package has been created for performing 
network meta-analysis and it was useful for this study since multiple groups needed to be compared 
to the reference group even if there were not indirect comparisons (i.e. all the studies provided data 
for each of the considered CYP2C19 metabolic phenotypes). Phenotypic groups were compared using 
the wild-type EM as the reference group.  A random-effects meta-analysis was carried out for 
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completeness and comparison of findings. Standardized mean difference (SMD) or odds ratio (OR) 
with 95% confidence intervals (CI) were calculated. Heterogeneity across studies was assessed using 
I2 and Cochran’s Q (Higgins et al., 2003).  
This meta-analysis provided 80% power to identify an effect size (SMD) of d=0.40 when comparing 
PMs (the smallest group, n=51) with EMs (the reference group, n=1049) for a continuous outcome 
and OR=2.21 for a binary outcome, at a significance level of 0.05 (Faul et al., 2007). 
We estimated that a corrected p value of 0.008 would account for the six independent tests that were 
carried out (improvement and response were correlated and considered as one test; the five side effect 
outcomes were considered as independent outcomes). Side effects at different weeks are not 
independent. Each outcome was tested five times comparing EMs with other functional groups, but 
CYP2C19 metabolic groups are a consolidated classification with precise functional and biological 
meaning that represents a useful guide in interpreting findings. A more stringent multiple-testing 
correction would also take into account the comparisons between EMs and other CYP2C19 functional 
groups (0.008/5=0.0016), but we suggest that the known functional interpretation of CYP2C19 groups 
may be a valid alternative to strict statistical rigour in this context. 
 
3. Results 
A description of the clinical-demographic characteristics of the included samples is provided in 
Supplementary Table 1. There was no difference in mean citalopram or escitalopram dose by 
CYP2C19 metabolic phenotypes at study endpoint in GENDEP, STAR*D and PGRN-AMPS (dose 
information was not available in GenPod). The distribution of phenotypic groups in the analysed 
samples is reported in Supplementary Table 3A. Imputation quality was high in all samples for both 
polymorphisms (R2 between 0.95 and 0.99 (Li et al., 2010)). GENDEP participants had 97.6% 
consistency between genotyped and imputed SNPs (Supplementary Table 3B).  
 
3.1. Treatment efficacy 
In total, 2558 patients were included in the meta-analysis. The distribution of efficacy outcomes 
across CYP2C19 metabolic phenotypes was reported in Supplementary Table 4. Compared to EMs, 
PMs had higher symptom improvement scores (SMD=0.43, CI=0.19-0.66, p=0.00037) and higher 
remission rates (OR=1.55, CI=1.23-1.96, p=0.00025), with low or absent heterogeneity (I2 was 11.5% 
and 0%, respectively). Other CYP2C19 metabolic phenotypes did not show different outcomes 
compared to EMs (Supplementary Table 5 and Figure 1). Results did not change using a random-
effects model.   
3.2. Treatment side effects  
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Across STAR*D, GENDEP and PGRN-AMPS 2037 patients were included in the analysis. The 
distribution of side effects across CYP2C19 metabolic phenotypes was reported in Supplementary 
Table 6. At weeks 2-4, PMs showed higher risk of gastro-intestinal side effects (OR=1.26, CI=1.08-
1.47, p=0.0033), of CNS side effects (OR=1.28, CI=1.07-1.53, p=0.0068) and of sexual side effects 
(OR=1.52, CI=1.23-1.87, p=0.0001) (Supplementary Table 5 and Figure 2). Considering a corrected 
p threshold of 0.008, all these side effects were significantly more frequent in PMs. At week 6, PMs 
showed higher risk of sexual side effects (OR=1.64, CI=1.23-2.17, p=0.0007) but no higher risk of 
other side effects. For all these comparisons heterogeneity was low (I2 range 0%-24%).  No difference 
was seen at week 8-9 for any side effect, except a weak non-significant trend for sexual side effects. 
No difference in total side effects burden was observed at any time point when we considered the risk 
of having side effects in the highest quartile of the distribution in each sample. A non-significant 
effect of higher total side effects was observed in PMs at week 2 (p=0.03) for the continuous measure 
of side effect severity (Supplementary Table 5 and Supplementary Figure 1). CYP2C19 IM+ group 
was the only metabolic phenotype to show higher risk of drop out at week 4 (OR=1.80, 95% CI=1.08-
3.00, p=0.024), but this association did not survive multiple-testing correction. PMs did not show 
higher risk of dropout at week 4 (OR=1.16, CI=0.38-3.58). Other CYP2C19 phenotypic groups did 
not show relevant differences compared to EMs, except lower risk of cardiovascular side effects and 
sleep side effects in EM+ at weeks 2-4 (OR=0.77, CI=0.64-0.92, p=0.0048) and 6 (OR=0.84, 
CI=0.75-0.95, p=0.0039), respectively, and higher risk of CNS side effects at week 8 in UMs 
(OR=1.26, 95% CI=1.04-1.53, p=0.019), but the latter did not survive multiple-testing correction. 
The use of a random-effects model did not change the results.  
Excluding those side effects there were already present at baseline in drug-free patients in GENDEP, 
results did not change, except that PMs showed higher risk of gastro-intestinal side effects also at 
week 6 (OR=1.47, CI=1.13-1.92, p=0.004). In addition, the trend of higher sexual side effects in PMs 
at weeks 8-9 was not observed, the lower risk of cardiovascular side effects in EM+ at weeks 2-4 
became a non-significant trend (OR=0.82, CI=0.67-0.99) and there was a non-significant trend of 
higher gastro-intestinal side effects in PMs at weeks 8-9 (OR=1.35, CI=1.01-1.81).   
 
 
4. Discussion 
This study shows that CYP2C19 PMs had higher symptom improvement and higher remission 
probability compared to EMs during treatment with citalopram or escitalopram (Figure 1). The 
observed SMD of 0.43 in symptom improvement between PMs and EMs is statistically considered 
close to a medium effect size (0.50) (Faraone, 2008). Statistical outcomes cannot be equated with 
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clinical relevance and a clinical relevance cutoff of SMD=0.24 was proposed based on the effect size 
observed for antidepressant drugs (SMD=0.31, CI=0.27-0.35) and psychotherapy (SMD=0.25, CI= 
0.14-0.36) in depression (Cuijpers et al., 2014). Other CYP2C19 metabolic phenotypes, including 
UMs, showed no differences in efficacy outcomes compared to EMs. In addition to increased 
treatment efficacy, PMs showed higher risk of gastro-intestinal, CNS and sexual side effects early in 
treatment (particularly during the first 2-4 weeks), but not later in treatment (weeks 8-9) (Figure 2). 
The highest effect size was observed for the risk of sexual side effects at weeks 2-4 and 6 (OR=1.52 
and 1.64, respectively) and this was the only side effect association that survived a stringent multiple-
testing correction (considering the comparisons between EMs and other CYP2C19 functional groups 
the multiple testing corrected p-value would be 0.0016). At week 4, PMs did not show a higher burden 
of total side effects and had no higher risk of dropout. The risk of dropout due to side effects was 
assumed to be the highest during the first 4 weeks of treatment, but data reporting the observed cause 
of dropout were not available. Mean antidepressant dose was not different among CYP2C19 
metabolizing groups. These results suggest that although some side effects were more common in 
PMs in the first weeks of treatment, overall they were not more troubling than in other CYP2C19 
groups and they may be balanced by higher improvement in depressive symptoms.  
These findings are consistent with a previous STAR*D study that investigated remission and 
tolerance to citalopram (Mrazek et al., 2011), where tolerance represents a measure of side effect 
level. Tolerance was defined as continuation of citalopram treatment after the completion of Level 1 
of the STAR*D trial. Previous studies in GENDEP and STAR*D failed to establish association 
between CYP2C19 metabolizer status (PM vs. EM) and response, side effects or study retention 
(Peters et al., 2008; Hodgson et al., 2015; Hodgson et al., 2014), but individual studies would have 
limited power given the low number of subjects with PM metabolic phenotype (~2% of all patients 
analysed), particularly in GENDEP which has only six PM subjects. A previous analysis of CYP2C19 
in GENDEP used different definitions of side-effect, investigating each ASEC item and the sum of 
ASEC items (Hodgson et al., 2015). 
No difference in treatment efficacy or side effects was identified between UMs and EMs, except for 
a non-significant higher risk of CNS side effects only at weeks 8-9 (Figure 2) that was probably the 
effect of random noise.  
The only phenotypic group that showed lower risk of side effects was EM+ (lower risk of sleep side 
effects at week 6 and of cardiovascular side effects at weeks 2-4), suggesting that weak differences 
may depend on metabolic level but the UM group may have not provided enough power to observe 
them (~4-5% of patients were UMs in the analysed samples).  
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In addition to pharmacokinetic mechanisms, pharmacodynamic mechanisms may be involved in the 
association between CYP2C19 and antidepressant response, since CYP2C19 activity was reported to 
influence central neurotransmitters and neurotrophins relevant to antidepressant mechanisms of 
action (Jukić et al., 2016).  
Our results conflict with the recommendation, based on pharmacokinetic parameters, of a 50% 
reduction in the starting dose of citalopram/escitalopram in CYP2C19 PMs (Hicks et al., 2015), since 
we showed that a standard dose was associated with greater efficacy without higher drop-out rates. 
Antidepressant treatment with citalopram/escitalopram may be particularly indicated in CYP2C19 
PMs given the efficacy profile, if appropriate clinical support and monitoring is provided and the 
patient is informed of potential side effects at the beginning of the treatment. Effective plasma (and 
brain) drug concentrations may be reached in a higher proportion of PMs than other metabolic 
phenotypes, at the price of more frequent early side effects. The correlation between escitalopram 
serum concentration and treatment response was showed to be nearly-asymptotic, with poor 
antidepressant response at sub-therapeutic plasma concentration and stable response at therapeutic 
plasma concentration (Florio et al., 2017). When the threshold serum concentration is reached (which 
corresponds to serotonin transporter occupancy of 80%), further dose increase does not improve 
response. However, no definite drug plasma concentration threshold was identified in existing 
studies, thus drug plasma concentration has poor usefulness to guide dose prescription. The good 
tolerability profile of citalopram/escitalopram implies that side effects are usually not troubling, 
which may not be true for other antidepressants, such as tricyclic antidepressants (TCAs) or 
venlafaxine (Cipriani et al., 2012; Cipriani et al., 2009). It should be noted that TCAs and venlafaxine 
have specific profiles of efficacy and they represent valid alternatives to SSRIs as currently reported 
in clinical guidelines, but it should not be assumed that the current results referred to CYP2C19 PMs 
can be applied to antidepressants different from citalopram and escitalopram. 
The limitations and strengths of this study should be considered. This was the first meta-analysis to 
investigate the role of CYP2C19 metabolic phenotypes in citalopram/escitalopram efficacy/side 
effects, individual level data were available in all samples and the total sample size was the largest 
ever used for investigating this topic. On the other hand, PMs are rare in the Caucasian population 
resulting in limited power to identify differences involving this group even in this sample of 2558 
patients. Side effect assessment was not available in all samples, and at weeks 6 and 8-9 part of 
patients dropped from the study and side effects data could not be imputed because it would be 
unreliable. At weeks 6 and 8-9, respectively, side effects were available in 84.4% and 73.6% of the 
initial sample in STAR*D, while in 85.9% and 83.3% of the initial sample in GENDEP. In PGRN-
AMPS 87% of patients initially included had side effect data at week 4 and 80% at week 8 (sample 
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size for this analysis is reported in Supplementary Table 6). Our findings suggest that CYP2C19 PMs 
may benefit from standard doses of citalopram/escitalopram, with a higher response than other 
metabolic phenotypes. No conclusions could be drawn for UMs since which showed no significant 
differences in outcomes compared to EMs, and the study was probably under-powered to detect weak 
effects. EM+ was the only group showing lower risk of some side effects compared to EMs. We 
observed no to low heterogeneity among studies for both efficacy and side effects. For the former 
group all samples showed similar better outcome in PMs compared to EMs except GenPod, which 
included only three PM patients explaining the marginal effect on heterogeneity. Finally, the possible 
confounding effect of CYP2C19 enhancers/inhibitors was not assessed, but a previous analysis in 
GENDEP concluded that the exclusion of subjects with concomitant use of enhancers/inhibitors did 
not change the pattern of results (Hodgson et al., 2014).  
In conclusion, this meta-analysis shows good efficacy in CYP2C19 poor metabolisers with 
citalopram/escitalopram, contrasting previous pharmacokinetic findings (Hicks et al., 2015). Our 
results show better treatment outcomes in PMs treated with standard doses with no relevant impact 
on late side effects (after the 6th week of treatment). Careful information for patients and monitoring 
of side effects during the early phase of treatment are recommended. Other CYP2C19 metabolic 
phenotypes, including UMs, did not show differences in efficacy or side-effect outcomes compared 
to EMs. An interesting implication of this study is the possibility to derive CYP2C19 metabolic 
groups from standard genome-wide data with a good level of quality. 
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Figure 1: meta-analysis results for improvement and remission. PM=poor metabolizers: 
IM=intermediate metabolizers; IM+= intermediate metabolizers plus; EM=extensive metabolizers; 
EM+= extensive metabolizers+; UM=ultrarapid metabolizers. EM was taken as reference group. 
SMD=standardized mean difference. CI=confidence interval. 
Symptom improvement Remission 
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Quantifying heterogeneity/inconsistency: 
tau^2 = 0.0033; I^2 = 11.5% 
Quantifying heterogeneity/inconsistency: 
tau^2 = 0; I^2 = 0% 
Test of heterogeneity/inconsistency: 
Q=16.94, df=15, p=0.32 
Test of heterogeneity/inconsistency: 
Q=12.47, df=15, p=0.64 
 
 18 
Figure 2: meta-analysis results for side effects. PM=poor metabolizers: IM=intermediate metabolizers; IM+= intermediate metabolizers plus; 
EM=extensive metabolizers; EM+= extensive metabolizers+; UM=ultrarapid metabolizers. EM was taken as reference group. SMD=standardized 
mean difference. CI=confidence interval. For each comparison heterogeneity is quantified using tau^2, I^2 and assessed using Q test.  
 
Gastro-intestinal side effects at weeks 2-4 Gastro-intestinal side effects at week 6 Gastro-intestinal side effects at weeks 8-9 
  
 
tau^2 = 0; I^2 = 0% 
Q=5.54, df=10, p=0.85 
tau^2 = 0; I^2 = 0% 
Q=1.96, df=5, p=0.85 
tau^2 = 0; I^2 = 0% 
Q=7.6, df =10, p=0.67 
Cardiovascular side effects at weeks 2-4 Cardiovascular side effects at week 6 Cardiovascular side effects at weeks 8-9 
   
tau^2 = 0; I^2 = 0% 
Q=7.48, df=10, p=0.68 
tau^2 = 0; I^2 = 0% 
Q=2.05df=5, p=0.84 
tau^2 = 0; I^2 = 0% 
Q= 3.29, df=10, p=0.97 
 
 
 
 
  
 19 
   
   
CNS side effects at weeks 2-4 CNS side effects at week 6 CNS side effects at weeks 8-9 
   
tau^2 = 0.0011; I^2 = 5.2% 
Q=10.55, df=10, p=0.39 
tau^2 = 0; I^2 = 0% 
Q=0.68, df=5, p=0.98 
tau^2 = 0.0018; I^2 = 4.8% 
Q=10.51, df=10, p=0.40 
Sleep side effects at weeks 2-4 Sleep side effects at week 6 Sleep side effects at weeks 8-9 
   
tau^2 = 0; I^2 = 0% 
Q=4.24, df=10, p=0.94 
tau^2 = 0; I^2 = 0% 
Q=3.24, df=5, p=0.66 
tau^2 = 0; I^2 = 0% 
Q=4.57, df=10, p=0.92 
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Sexual side effects at weeks 2-4 Sexual side effects at week 6 Sexual side effects at weeks 8-9 
   
tau^2 = 0; I^2 = 0% 
Q=6.89, df=10, p=0.74 
tau^2 = 0.0152; I^2 = 24% 
Q=6.58, df=5, p=0.25 
tau^2 = 0; I^2 = 0% 
Q=9.95, df=10, p=0.45 
 
